Selective inhibitors of nuclear export SINE in hematological malignanciesReport as inadecuate

Selective inhibitors of nuclear export SINE in hematological malignancies - Download this document for free, or read online. Document in PDF available to download.

Experimental Hematology and Oncology

, 4:7

First Online: 01 March 2015Received: 21 December 2014Accepted: 03 February 2015DOI: 10.1186-s40164-015-0002-5

Cite this article as: Das, A., Wei, G., Parikh, K. et al. Exp Hematol Oncol 2015 4: 7. doi:10.1186-s40164-015-0002-5


Regulated nucleo-cytoplasmic transport plays a major role in maintaining cellular homeostasis. CRM1 chromosome region maintenance 1 or exportin 1 or XPO 1 is responsible for the nucleo-cytoplasmic transport of more than 200 proteins, including most of the tumor suppressor proteins TSP. CRM1 is overexpressed in pancreatic cancer, osteosarcoma, glioma, cervical and hematological malignancies. This inspired the development of novel agents that selectively inhibit nuclear exportins SINEs. In this review we focus on the significance of CRM1 in carcinogenesis and review the new development of SINE inhibitiors in hematological malignancies. Selinexor KPT-330 as the first-in-human SINE agent represents this novel class of anti-cancer agents.

KeywordsSelective inhibitor of nuclear export SINE Slinexor KPT-330  Download fulltext PDF

Author: Arundhati Das - Guoqing Wei - Kaushal Parikh - Delong Liu


Related documents